Illumina Ventures is a venture capital firm focused on investing in early-stage companies in the genomics and precision health sectors. They aim to build an ecosystem and translate investment into innovation, accelerating the impact on human health. The firm leverages its domain expertise, operating experience, and strategic relationship with Illumina (NASDAQ: ILMN) to identify and build companies that will transform healthcare. Illumina Ventures operates as true partners to entrepreneurs, supporting the development of breakthrough science and technology into market-leading companies. Through Illumina Ventures Labs, they accelerate value creation for early-stage genomics start-ups by providing access to capital, sequencing, mentorship, and fully equipped genomics lab capabilities.
Preferred startup development maturity for initial funding deployment.
Life Sciences Tools, Diagnostics, Therapeutics, Digital Health, Sustainability, Single cell analysis, Spatial biology, Multi-omic profiling, Synthetic biology, Molecular characterization, Infectious disease diagnostics, Cell free DNA, RNA and protein analysis, Pediatric genomics, Point of care solutions, Cell and gene therapies, Gene editing platforms, AI-enabled drug discovery, Nonviral delivery systems, Therapeutic protein libraries, Virtual care delivery, Patient engagement and care navigation, AI/ML enabled clinical care innovation, Agricultural biotechnology, Biomanufacturing, Bioremediation, Bioexploration
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...